In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn't get the organ to a recipient in time.

A new medical technology expected to be on the market in 2027 is poised to help patients in middle America have greater access to heart transplants. Xvivo Perfusion, a leader in organ transplant ...

The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group’s investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the ...

ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

Please provide your email address to receive an email when new articles are posted on . Most respondents reported they would undergo a donation procedure that maximized use of their organs. Many ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. TransMedics Group (NasdaqGM:TMDX) received full FDA approval for its ...

In the majority of cases, graft failure after heart transplantation is attributable to abnormalities like severe coronary artery disease. As donors with extended criteria like advanced age and ...

The emerging advantages of positron-emission tomography (PET) myocardial perfusion imaging (MPI) for coronary artery disease (CAD) diagnosis and assessment of cardiovascular event risk has prompted ...

Perfusion describes when fluids such as blood and lymph pass through tissue. A perfusionist is a professional who operates machinery when this process requires assistance, such as during heart surgery ...